The Runx genes present a challenge to the simple binary classification of cancer genes as oncogenes or tumor suppressors. There is evidence that loss of function of two of the three mammalian Runx genes promotes cancer, but in a highly lineage-restricted manner. In human leukemias, the RUNX1 gene is involved in various chromosomal translocation events that create oncogenic fusion proteins, at least some of which appear to function as dominant-negative inhibitors of the normal gene product. Paradoxically, evidence is mounting that structurally intact Runx genes are also oncogenic when overexpressed. All the three murine genes act as targets for transcriptional activation by retroviral insertional mutagenesis, and the oncogenic potential of Runx2 has been confirmed in transgenic mice. Moreover, the RUNX1 gene is often amplified or overexpressed in cases of acute leukemia. The state of progress in elucidating the oncogenic roles of the Runx genes is the subject of this review, and we draw together recent observations in a tentative model for the effects of Runx deregulation on hematopoietic cell differentiation. We suggest that lineage-specific factors determine the sensitivity to the oncogenic effects of loss or overexpression of Runx factors.
Introduction
The historical classification of cellular genes involved in cancer is a simple binary system with two general categories -the oncogenes and the tumor-suppressor genes. The cellular oncogenes are defined as genes that act in a dominant manner to promote cancer and are derived from their normal counterparts, the protooncogenes, by activating mutations or transcriptional deregulation (Bishop, 1987) . In contrast, tumorsuppressor genes are recessive genes whose functions are lost in the cancer cell (Knudson, 1986) . The tumorsuppressor genes have been further classified into the gatekeepers and the caretakers, according to their roles in normal growth and development. Loss of either tumor-suppressor class may confer susceptibility to cancer, with varying degrees of predisposition (Shields and Harris, 2000) . The Runx genes present a challenge to the simple binary classification of cancer genes as they display the hallmarks of both oncogenes and tumor suppressors, albeit in different lineage and cellular contexts.
The three mammalian Runx genes encode transcription factors with distinct roles in normal development and tissue-specific patterns of expression. They bind DNA through a conserved structure, the Runt domain, and share a common heterodimeric binding cofactor, CBFb. The Runx genes have the potential to encode numerous isoforms due to alternative promoter usage and variable splicing (Levanon et al., 1996) . The functional significance of this complex organization and coding potential is largely unclear, although there is some evidence of antagonism between full-length and truncated isoforms (Tanaka et al., 1995) . This complexity also confounds comparison between studies, as does the variety of nomenclature systems that have been applied to the Runx isoforms. Figure 1 provides a diagrammatic summary of the basic structure of the vertebrate Runx genes and their products for the purposes of this review.
In combination with CBFb, RUNX factors can act as either activators or repressors of target gene expression and the highly context-dependent outcome of RUNX expression reflects the large number of transcription factors, coactivators and corepressors that have been shown to interact with RUNX Wheeler et al., 2000) . Like their Drosophila homologue Runt (Canon and Banerjee, 2000) , the mammalian Runx proteins appear to regulate development at specific decision points, where progenitor cell fate is balanced between proliferation, differentiation and cell death. The potential of Runx factors to enhance or diminish homeostatic controls may hold the key to their paradoxical roles in cancer.
Runx genes as dominant oncogenes

Chromosomal translocations and RUNX1
The first evidence that deregulated expression of Runx genes may contribute to leukemogenesis was provided by the discovery of RUNX1 (AML1) as one of the target genes affected by the common t(8;21) chromosomal translocation in acute myeloid leukemia (Miyoshi et al., 1991 (Miyoshi et al., , 1993 Erickson et al., 1992; Nisson et al., 1992) . Since then, many translocations have been described involving RUNX1. Most of these result in replacement of the C-terminal transactivation domain of RUNX1 with heterologous protein sequences derived from a fusion partner gene. This class of translocation is almost exclusively associated with myeloid leukemias. A second type of translocation is TEL-RUNX1, which is found in 20-25% of Pre-B acute lymphoblastic leukemia (B-ALL). The t(12;21) fuses the 5 0 portion of TEL to almost the entire coding sequence of RUNX1, which is consequently expressed under the control of the TEL locus (Golub et al., 1995; Romana et al., 1995) .
The fact that the entire Runt domain of RUNX1 is retained in all fusions argues that this is an essential functional component of the oncogenic translocation products. However, the consistent presence of a heterologous protein partner leaves open the possibility that oncogenic activity is a novel property of the fusion product rather than an intrinsic feature of RUNX1 or its fusion partners. Moreover, the perplexing puzzle which is yet to be satisfactorily resolved is the strict lineage specificity of the different translocations. This may reflect the tissue-restricted oncogenic spectrum of the fusion proteins themselves, as indicated by recent studies involving the introduction of RUNX1-ETO into mouse bone marrow cells, which partially recapitulated the specific abnormalities of myeloid development seen in patients bearing this translocation (de Guzman et al., 2002) .
RUNX1 transformation in vitro
The first evidence that the intact RUNX1 gene might have intrinsic oncogenic potential came from experiments in 3T3 fibroblast cells, where ectopic RUNX1-P2 (AML1b) was found to induce morphological transformation and tumorigenic conversion, a process that required an intact and functional Runt DNA-binding domain (Kurokawa et al., 1996a, b) . However, a similar study which used the RUNX1-P1 (AML1c) form did not observe such growth effects . The reason for this disparity is not clear, but may relate to the use of the different N-terminal isoforms or the heterogeneity of 3T3 cell populations. In this context, it is of interest that enforced RUNX1 expression in primary murine embryonic fibroblasts was recently found to induce growth arrest and a premature senescence-like phenotype, a process which did not occur in mutant cells lacking p19 ARF (Linggi et al., 2002) . Other properties suggestive of dominant oncogenic potential have been attributed to RUNX1, including the acceleration of progression to the S phase in 32Dcl3 myeloid cells (Strom et al., 2000) and the ability to rescue proliferation in both 32Dcl3 myeloid and Ba/F3 lymphoid cells expressing dominant-negative inhibitors (Lou et al., 2000; Bernardin and Friedman, 2002) . Moreover, a recent study on sea urchin development revealed a strong correlation between proliferating tissues and expression of the Runx homologue (Robertson et al., 2002) SpRunt, which appears to be required for cell division during embryogenesis (Coffman, 2003) .
Retroviral activation of Runx genes in murine lymphomas
Strong evidence that deregulated expression of Runx genes may contribute to leukemogenesis came from retroviral tagging experiments conducted in the lymphoma-prone CD2-MYC transgenic mice. A novel common insertion site, til-1, was identified in around a third of virus-accelerated tumors (Stewart et al., 1996) , and subsequently mapped to the P1 promoter of Runx2. Insertions at til-1 juxtapose the viral LTR enhancer elements with the normal Runx2 promoter, resulting in ectopic expression of full-length Runx2 RNA and protein, along with a range of truncated and variant isoforms (Stewart et al., 1997) . Subsequently, it was shown that both Runx3 and Runx1 could act as targets in the CD2-MYC model, albeit at a much lower frequency Wotton et al., 2002) . The common result of these insertions was found to be overexpression of structurally intact Runx gene products (Stewart et al., 1997; Wotton et al., 2002) . Since tumors carried insertions at only one Runx gene, it is possible that the oncogenic effects of the three genes are redundant in this context. Insertions at Runx1 and Runx3 have also been reported in high-throughput screens of retrovirally induced leukemias Lund et al., 2002; Mikkers et al., 2002; Suzuki et al., 2002; Kim et al., 2003) , confirming that retroviral activation of this gene family is not restricted to the CD2-MYC transgenic model.
An interesting feature of the retroviral insertions observed so far is that these are exclusively directed to the Runx P1 promoters, which are distant from the coding exons and encode products with distinct Ntermini from the proximal P2-derived isoforms (Stewart Figure 1 Generic structure of the human RUNX and mouse Runx genes. These genes share a dual promoter and exon/intron structure. Isoforms generated from the distal (P1) promoter have a distinctive N-terminal sequence due to the use of translational initiator in the short exon 1 and splicing which bypasses the P2 initiator codon. Runx3 is the simplest and smallest of the three genes, with the shortest distances between exons and promoters (Bangsow et al., 2001) . Only the exons conserved between all genes (1-6) are shown in the diagram. Runx1 and 2 have additional internal and 3 0 exons, with the capacity to encode a larger range of isoforms by exon skipping and alternative splicing. Exon sizes and distance are not to scale. RD: sequences encoding the conserved Runt domain; TA: sequences encoding the conserved transactivation domain and C-terminal VWRPY motif et al Wotton et al., 2002) . This does not necessarily imply that the P1 isoforms are intrinsically more oncogenic. Alternative explanations are that the P1 promoters are more readily activated by the retroviral LTR or that the P1 isoforms are more efficiently translated, as reported for the human RUNX1 gene (Pozner et al., 2000) .
One potential caveat with these experiments is the theoretical possibility that insertional activation of Runx genes may itself potentiate the leukemogenic capacity of the virus via the Runx-binding sequences within the LTR core enhancer (Zaiman et al., 1995) . Corroborating evidence that Runx genes have intrinsic oncogenic potential was therefore required.
A wild-type Runx gene is oncogenic in transgenic mice
The oncogenic potential of the full-length Runx2 P1 isoform was confirmed in transgenic mice in which the relevant cDNA is expressed under the control of the CD2 promoter (Vaillant et al., 1999) . This finding was important as it excluded antagonism by truncated or variant isoforms as the basis of the oncogenic action of proviral insertion at til-1. Retroviral infection experiments and crossbreeding with CD2-MYC transgenics confirmed the strong synergistic interaction between Runx2 and Myc in the genesis of murine T-cell lymphomas. However, Runx2 is also capable of collaborating with p53 loss as well as Pim-1 and Myb, which, together with MLV insertion patterns, suggests that the oncogenic properties of Runx may be distinct from those previously identified in lymphoid systems (Blyth et al., 2001 ).
An interesting feature of the CD2-Runx2 model is that the predisposition to T-cell neoplasia is accompanied by perturbed thymocyte development (Vaillant et al., 1999 . In addition, the phenotype of the resulting clonal tumors is indistinguishable from the expanded population that characterizes the preneoplastic phase. These observations suggest that Runx2 overexpression is insufficient for lymphoma development but may impede normal differentiation, thus producing an enlarged pool of cells especially vulnerable to additional transformation events. CD2-Runx1 mice have been described (Hayashi et al., 2001 ), but to date there have been no reports of a leukemic predisposition in these animals. However, a threshold level of deregulated Runx gene expression may be required to manifest the tumor phenotype in these animals as studies on CD2-Runx2 mice have shown that the oncogenic phenotype is gene dose dependent (Cameron et al., 2003) . Alternatively, it is possible that while the three Runx genes appear to be interchangeable as targets for retroviral activation, Runx1 and Runx2 transgenes may differentially affect T-cell development (Hayashi et al., 2001; Vaillant et al., 2002) .
Amplification of RUNX1 in B-ALL
Amplification of a specific chromosomal region in the cancer cell genome is generally assumed to be selected on the basis of overexpression of a dominant oncogene within the amplicon. There have been a number of reports documenting amplification of the 21q22 region and specifically RUNX1 in B-ALL, with the number of additional copies ranging from 1 to 13 (Niini et (Harewood et al., 2003) allowed some general features of RUNX1 amplifications in ALL to be identified. The incidence appears to be higher in children than in adult ALL patients and the most frequent anomaly is the presence of a marker chromosome carrying multiple copies of the apparently intact RUNX1 gene. In all patients, the karyotype was neardiploid, with the abnormal maker chromosome replacing one copy of the normal chromosome 21. All presented with relatively low WBC counts and had pre-B or common phenotypes. In this series, the median age of the patients was older (9 years) than that normally seen in cases of childhood ALL. While it is conceivable that amplification of RUNX1 serves to potentiate the effects of a mutated isoform, this would appear unlikely as sequence analyses of the Runt domain coding exons failed to detect mutations (Busson-Le Coniat et al.,
2001; Penther et al., 2002).
It is tempting to speculate that increased RUNX1 gene dosage is functionally relevant to the unusually high incidence and distinctive spectrum of hematological disease observed in children with Down's syndrome (Rowley, 1981; Lange, 2000; Hasle, 2001 ). The incidence of ALL is approximately 10-fold higher in DS children, who also show a very high incidence of MDS and AML, but with a strong bias towards the relatively unusual megakaryocyte phenotype (AML-M7) and a deficit in leukemias of granulocytic lineages. Moreover, DS neonates experience a unique self-resolving transient myeloproliferative disease (TMD) that is clonal and phenotypically identical to AML-M7. This distinct disease phenotype is intriguing in the light of recent findings that RUNX1 plays an essential role in development of the megakaryocyte lineage (Elagib et al., 2003) . Thus, it is possible that alterations in RUNX1 gene dosage can predispose to the megakaryocyte disorders observed in DS patients.
RUNX loss of function and cancer
The earliest indication that loss of Runx function might be a key event in leukemogenesis came from the observation that RUNX1 fusion proteins can antagonize the function of the wild-type gene product in a variety of transcriptional reporter assays (Frank et al., 1995; Meyers et al., 1995; Hiebert et al., 1996; Fears et al., 1997; Uchida et al., 1999) . Moreover, the effect of knocking in the RUNX1-ETO fusion generated a remarkably similar phenotype to the RUNX1 knockout model, with failure of definitive hemopoiesis, again arguing that the fusion protein acts as a dominant-negative antagonist of the remaining wild-type allele (Yergeau et al., 1997; Okuda et al., 1998) . As a caveat, it should be noted that RUNX1-ETO may have additional properties as the knockin mice display dysplastic hemopoietic progenitor cells with increased self-renewal, a feature not seen in simple loss of function models (Okuda et al., 1996 (Okuda et al., , 1998 Wang et al., 1996) . Moreover, RUNX1-ETO can modulate gene targets not normally regulated by RUNX1 (Klampfer et al., 1996; Shimada et al., 2000) .
Further indication that Runx loss of function is leukemogenic comes from the involvement of the heterodimeric binding partner CBFb in a frequent chromosomal translocation (Inv16) that generates fusion proteins with apparent dominant-negative function. Inv16, which is specifically associated with the M4Eo subtype of AML, results in juxtaposition of CBFb to MYH11 gene sequences (Liu et al., 1993) . This generates a chimeric product capable of inhibiting RUNX1 function (Cao et al., 1997; Kanno et al., 1998) , mimicking Runx1 loss in vivo (Castilla et al., 1996) , perturbing granulocyte differentiation (Kogan et al., 1998) and contributing to acute leukemia in mouse models (Castilla et al., 1999; Yang et al., 2002) . Two alternative theories have been proposed to explain the mode of action of CBFb-MYH11; either it acts as a constitutive repressor of RUNX target genes (Lutterbach et al., 1999; Durst et al., 2003) or it sequesters RUNX1 in the cytoplasm (Adya et al., 1998; Lukasik et al., 2002) , thus antagonizing both its activator and repressor functions.
More recently, it has been established that some cases of AML harbor inactivating and/or dominant-negative mutations in RUNX1. In particular, cases of AML-M0 were shown to carry a high frequency (22%) of, usually biallelic, RUNX1 mutations (Preudhomme et al., 2000) . Moreover, RUNX1 loss of function mutations underlie familial platelet disorder, a syndrome which features predisposition to myeloid leukemia (Song et al., 1999) . In contrast, no RUNX1 mutations were found in a series of 41 ALL patients (Preudhomme et al., 2000) , although sporadic RUNX1 mutations have been reported by others (Osato et al., 1999; Song et al., 1999) .
Evidence that RUNX3 loss of function also predisposes to cancer has come from the finding that this gene is hypermethylated and downregulated in human gastric carcinomas . Moreover, mice lacking Runx3 were found to develop gastric epithelial hyperplasia and tumors when crossed to a p53 null background . However, conflicting data regarding the Runx3 À/À phenotype exist and these discrepancies remain to be fully resolved (Levanon et al., 2002) .
While there is mounting evidence that loss of RUNX function is involved in some cancers, the lineage specificity of these effects is striking. Experiments carried out with Runx1 haploinsufficient (Runx1 þ /À ) mice showed that reduced Runx1 dosage does not increase the rate of lymphoid tumor development in either MLV-infected or Runx2/MYC transgenic mice (Wotton et al., 2002) . These findings are consistent with the notion that reduced Runx1 function does not predispose to lymphoid malignancy, and that Runx2 does not exert its oncogenic effect by antagonizing Runx1 function. Furthermore, the lack of reported cancer predisposition in CCD patients and the current lack of evidence for RUNX2 loss of function in osteosarcomas suggest that a tumor-suppressor role may not extend to all gene family members and/or be relevant in all lineages associated with RUNX activity.
Contrasting roles for the Runx genes in myeloid and lymphoid neoplasia
As we have listed above, there is now good evidence to implicate the Runx genes as proto-oncogenes that can be activated by translocations, proviral insertion and amplification. At the same time, there is evidence for mutational loss of RUNX function in cancers, and that the RUNX fusion oncogenes act to antagonize the normal product. How can these apparently conflicting observations be reconciled? A potential clue is provided by the lineage-and stage-specific contexts in which Runx abnormalities have been detected, and leads us to propose the tentative model depicted in Figure 2 .
In myeloid leukemias, virtually all of the evidence points to RUNX1 loss of function as a key event. Figure 2 Model for the lineage-and stage-specific effects of deregulated Runx expression in the hemopoietic system. Arrows and block arrows indicate the promotion and inhibition of differentiation, while þ and À symbols indicate whether these effects are mediated by a deficit (À) or an excess ( þ ) of Runx activity, as discussed in the text. Germline Runx1 loss of function abolishes definitive hemopoiesis, while somatic mutation appears to result in differentiation failure at an early stage of myelopoiesis (M0). The RUNX1-ETO fusion is associated with a block at a later stage in myeloid development (M2). Runx overexpression is associated with interruption of differentiation in lymphoid neoplasia in the mouse, while amplification and overexpression of RUNX1 have been observed in human ALL. As discussed in the text, we suggest that TEL-RUNX1 is functionally similar to overexpression of an intact Runx gene with respect to its Runxrelated functions. Finally, we consider the possibility that increased RUNX1 gene dose in Down's syndrome may underlie disturbances in differentiation and the transient megakaryocytic leukemias experienced by affected individuals Although amplification of RUNX1 has been reported in a small number of patients with AML, it is unclear whether the RUNX1 gene is structurally intact in these cases (Kakazu et al., 1999; Hilgenfeld et al., 2001; Streubel et al., 2001) . Furthermore, RUNX1 mutations in non-M0 cases of myeloid leukemia are accompanied by chromosome 21 polysomy, with the additional copies of RUNX1 harboring the mutated allele rather than the normal allele (Preudhomme et al., 2000) . This demonstrates that, in myeloid leukemia, triosomy or tetrasomy of chromosome 21 is often associated with amplification of mutated RUNX1. In contrast, lymphoid neoplasia provides much more evidence for the dominant oncogenic role of Runx genes. All three genes can be activated by proviral insertions in murine T-cell lymphoma, while the human RUNX1 gene is subject to gene amplification and is highly expressed in many cases of ALL (Mikhail et al., 2002; Harewood et al., 2003) . Whether the other two RUNX genes can also functionally substitute for RUNX1 in this context is an interesting subject for further study.
Where does the TEL-RUNX1 translocation fit into this model? We note that this fusion differs from those found in myeloid leukemias in that virtually the entire coding sequence of RUNX1 is retained. Could the TEL-RUNX1 fusion be in some respects functionally analogous to overexpression of the normal RUNX1 product? In support of this notion, we note that t(12;21) and RUNX1 amplification have been observed as alternative events in cases of ALL of similar presentation, with virtually no overlap (Niini et al., 2000; Busson-Le Coniat et al., 2001; Dal Cin et al., 2001; Mathew et al., 2001; Jabber Al-Obaidi et al., 2002; Mikhail et al., 2002; Morel et al., 2002; Penther et al., 2002; Alvarez et al., 2003; Harewood et al., 2003) . This may be because they represent distinct oncogenic pathways. However, the similarity of the clinical picture and disease phenotype are consistent with the possibility that TEL-RUNX1 and amplification are functionally redundant. Another intriguing observation in this respect is that TEL-RUNX1 translocation is not a prominent feature of ALL in Down's syndrome, despite the increased incidence of disease in these children (Lanza et al., 1997) .
How does this hypothesis fit with the observations that the TEL-RUNX1 fusion has an enhanced capacity to recruit corepressors and antagonize RUNX1-dependent transcriptional activation in vitro? One possible rationale is that the critical function of RUNX in lymphoid neoplasia is gene repression, and that this can be mediated by augmented expression of any of the normal Runx genes or by the heightened activity of the fusion product (Figure 2 ).
Prospects
To date, the Runx genes have been primarily associated with malignant disease of the hematopoietic system. However, although knockout studies have emphasized critical lineage-specific effects, these genes are widely expressed in a number of tissues and organ systems. Furthermore, ectopic Runx expression has the potential to modulate growth in a range of cell lineages (Kurokawa et al., 1996b; Lou et al., 2000; Strom et al., 2000) and the combinatorial effects of deregulated Runx genes with lesions in the well-established oncosuppressor genes are profound (Blyth et al., 2001) . It seems likely that we are only at the threshold of understanding the full extent of RUNX involvement in human cancer.
